Latest News and Press Releases

FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I...

Ottawa, Sept. 22, 2025 (GLOBE NEWSWIRE) -- According to a study by Towards Healthcare, a sister company of Precedence Research, the global bipolar disorder treatment market size was estimated at USD...

Wilmington, Delaware, United States, March 13, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The market valuation in 2022 for the global ion exchange membrane market was US$ 1.2...

Selbyville, Delaware, June 13, 2023 (GLOBE NEWSWIRE) -- Vessel Sealing Devices Market size will cross USD 5 billion by 2032. The growing healthcare industry globally is creating a strong impetus...

AURORA, Ill., Jan. 17, 2023 (GLOBE NEWSWIRE) -- At Mental Health Technologies (MHT), they bring awareness to mental health concerns daily. However, each year everyone goes from the hustle and bustle...

Pune India, Jan. 14, 2023 (GLOBE NEWSWIRE) -- The market has been studied for the below mentioned-segmentation and regional analysis for North America, Europe, Asia, South America, and the Middle...

Chicago, June 29, 2022 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE For more information contact:                                                          KEVIN WILLIAMS, DBSA ...

Chicago, IL, May 12, 2022 (GLOBE NEWSWIRE) -- CHICAGO (May 12, 2022) – The Depression and Bipolar Support Alliance (DBSA), and its Scientific Advisory Board (SAB) will honor three clinicians for...

PORTLAND, Ore., Sept. 20, 2021 (GLOBE NEWSWIRE) -- The following is an open letter from Citizens For Mental Health Reform on our proposal to re-sentence all Oregon Psychiatric Security Review Board...

Phase 3 study of BXCL501 for the acute treatment of agitation associated with dementia expected to begin in Q4 2021 PDUFA date of January 5, 2022 assigned to BXCL501 NDA for the acute treatment of...